Study on the Antirejection Effects of the Dual ICOS and CD28 Antagonist Acazicolcept (ALPN-101) in Mouse Skin and Heart Transplantation Models. (PubMed, Transplantation) - Sep 11, 2026 - "Acazicolcept exhibits robust, superior antirejection efficacy compared with single-pathway blockades by concurrently inhibiting CD28 and ICOS signals. This dual mechanism effectively suppresses T-cell activation, effector memory differentiation, and the subsequent antibody-mediated response, offering a robust preclinical justification for its clinical advancement in solid organ transplantation."
IO biomarker • Journal • Preclinical • Solid Organ Transplantation • Transplantation • CD28 • CD69 • ICOS • PD-1
|
|
Jianxi Wang; Leigang Guo; Lin Li; Panpan Zhan; Tingting Ma; Xiaojingnan Ma; Yaojuan Liu; Zhen Yang; Zhongyang Shen
|